SecSonar.com

Amgen Inc. (AMGN)

Amgen Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Amgen Inc. (AMGN) is a Drug Manufacturers - General company based in US with a market capitalization of $180.9B. Revenue grew 9.9% year-over-year and the company generated $8.1B in free cash flow. This page tracks AMGN's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 28K employees · IPO Jun 17, 1983

Valuation

Valuation & price

$332.82 · as of May 13, 2026 · -14.3% vs 52w high

23.4

P/E ratio

Latest-FY diluted EPS

20.89

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$386$329$273Jul 25Dec 25Jul 26Jul 7, 25$292.95Jul 9, 25$296.52Jul 11, 25$295.27Jul 15, 25$292.51Jul 17, 25$298.25Jul 21, 25$295.87Jul 23, 25$309.22Jul 25, 25$306.58Jul 29, 25$303.56Jul 31, 25$295.10Aug 4, 25$301.94Aug 6, 25$284.67Aug 11, 25$285.09Aug 13, 25$289.33Aug 15, 25$296.47Aug 19, 25$295.55Aug 21, 25$295.76Aug 25, 25$288.47Aug 27, 25$287.97Aug 29, 25$287.71Sep 3, 25$283.85Sep 5, 25$283.64Sep 9, 25$279.97Sep 11, 25$282.73Sep 16, 25$273.08Sep 18, 25$275.83Sep 22, 25$286.00Sep 24, 25$279.22Sep 26, 25$272.98Sep 30, 25$282.20Oct 2, 25$297.40Oct 6, 25$294.12Oct 8, 25$294.62Oct 10, 25$290.13Oct 14, 25$293.85Oct 16, 25$295.81Oct 21, 25$301.14Oct 23, 25$292.89Oct 27, 25$291.16Oct 29, 25$291.77Oct 31, 25$298.43Nov 4, 25$296.70Nov 6, 25$315.59Nov 10, 25$323.66Nov 12, 25$336.28Nov 14, 25$336.74Nov 18, 25$343.99Nov 20, 25$336.07Nov 25, 25$341.11Nov 28, 25$345.46Dec 2, 25$338.36Dec 4, 25$340.16Dec 8, 25$321.23Dec 10, 25$315.38Dec 12, 25$317.74Dec 16, 25$326.74Dec 18, 25$324.42Dec 22, 25$331.39Dec 24, 25$333.96Dec 29, 25$329.63Jan 2, 26$327.64Jan 6, 26$330.17Jan 8, 26$330.11Jan 12, 26$325.54Jan 14, 26$328.97Jan 16, 26$330.41Jan 21, 26$343.60Jan 23, 26$344.75Jan 27, 26$351.32Jan 29, 26$342.94Feb 2, 26$344.68Feb 4, 26$366.20Feb 9, 26$375.82Feb 11, 26$366.58Feb 13, 26$369.19Feb 18, 26$379.73Feb 20, 26$374.75Feb 24, 26$382.87Feb 26, 26$379.33Mar 2, 26$385.70Mar 4, 26$379.27Mar 6, 26$369.53Mar 10, 26$375.43Mar 12, 26$367.79Mar 17, 26$361.13Mar 19, 26$349.92Mar 23, 26$349.77Mar 25, 26$353.93Mar 27, 26$348.77Mar 31, 26$351.85Apr 2, 26$347.94Apr 7, 26$340.00Apr 9, 26$355.60Apr 13, 26$349.82Apr 15, 26$348.22Apr 17, 26$355.30Apr 22, 26$345.92Apr 24, 26$344.55Apr 28, 26$339.57Apr 30, 26$346.25May 4, 26$323.85May 6, 26$331.11May 8, 26$331.70May 12, 26$336.29May 14, 26$336.23May 18, 26$324.39May 20, 26$331.57May 22, 26$339.30May 28, 26$336.48Jun 1, 26$329.13Jun 3, 26$338.22Jun 5, 26$349.58Jun 9, 26$344.57Jun 11, 26$354.06Jun 15, 26$350.53Jun 17, 26$341.66Jun 22, 26$344.72Jun 24, 26$351.43Jun 26, 26$358.33Jul 2, 26$374.15
$271.1852-week range$388.16
Loading valuation history…

Fundamentals

Key fundamentals

$180.9B

Market cap

9.9%

Revenue growth (YoY)

70.8%

Gross margin

$8.1B

Free cash flow (USD)

$45.5B

Net debt

-0.6%

Share dilution

2/4

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$23.0BFY 2017$22.8BFY 2018$23.7BFY 2019$23.4BFY 2020$25.4BFY 2021$26.0BFY 2022$26.3BFY 2023$28.2BFY 2024$33.4BFY 2025$36.7B
$23B$36.7B

Free cash flow by year

2016 → 2025

FY 2016$9.5BFY 2017$10.5BFY 2018$10.6BFY 2019$8.5BFY 2020$9.9BFY 2021$8.4BFY 2022$8.8BFY 2023$7.4BFY 2024$10.4BFY 2025$8.1B
$9.5B$8.1B

Gross margin by year

2021 → 2025

FY 202175.2%FY 202275.7%FY 202370.2%FY 202461.5%FY 202570.8%
75.2%70.8%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

1

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 1, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventAnnual Meeting ResultsMay 20, 2026Filing
  • 8-K eventExecutive AppointmentMay 19, 2026Filing
  • Insider sellInsider Sell $400KGrygiel Nancy A. · SVP & CCO · $400.5KMay 5, 2026Filing
  • Quarterly report10-Q FiledMay 1, 2026Filing
  • 8-K eventEarnings ReleaseApr 30, 2026Filing
  • 8-K eventExecutive DepartureApr 22, 2026Filing

Questions

Frequently asked questions

What is Amgen Inc.'s market cap?

Amgen Inc. (AMGN) has a market capitalization of $180.9B.

What is AMGN's P/E ratio?

AMGN trades at a price-to-earnings ratio of 23.4, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

What is AMGN's price-to-book (P/B) ratio?

AMGN trades at 20.89 times book value per share.

Are insiders buying AMGN stock?

SEC Form 4 filings show no open-market insider buys at Amgen Inc. in the last 90 days (1 sell).

Same arena

Related companies in Drug Manufacturers - General

GILD

Gilead Sciences, Inc.

$167.4B

PFE

Pfizer Inc.

$148.6B

SNY

Sanofi

$105.6B

GSK

GSK plc

$101.9B

NVS

Novartis AG

$287.1B

AZN

AstraZeneca PLC

$288.5B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.